Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01802567 · ClinicalTrials.gov registry record · NA
Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer
A NA study, sponsored by Giselle Sholler.
- Completed
- Registry status
- NA
- Development phase
- 52
- Enrollment target
NCT01802567 is a NA study that has completed, run by Giselle Sholler. The registered enrollment target is 52 participants.
The verdict
NCT01802567, a NA study, has completed, sponsored by Giselle Sholler.
- COMPLETED
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of this study is to test the feasibility (ability to be done) of experimental technologies to determine a tumor's molecular makeup (gene expression profile) and mutations. This technology called the "Pediatric Gene Analysis Platform" includes a genomic report (gene expression profile) and a DNA Mutation Panel Report that are being used to discover new ways to understand cancers and potentially predict the best treatments for patients with cancer in the future.
Interventions
- DEVICE Guided Therapy- Pediatric Gene Analysis Platform
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2013-03-04 |
| Est. Completion | 2024-01-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01802567
The ClinicalTrials.gov registry entry for NCT01802567 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Giselle Sholler, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Guided Therapy- Pediatric Gene Analysis Platform is the first listed.
NCT01802567 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01802567 about?
NCT01802567 is a clinical study titled "Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer". The purpose of this study is to test the feasibility (ability to be done) of experimental technologies to determine a tumor's molecular makeup (gene expression profile) and mutations. This technology called the "Pediatric Gene Analysis Platform" includes a genomic report (gene expression profile) an...
What is the current status of trial NCT01802567?
This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 2013-03-04. Estimated completion is 2024-01-17.
What interventions are being tested in trial NCT01802567?
The interventions under investigation include: Guided Therapy- Pediatric Gene Analysis Platform (DEVICE).
Who is sponsoring clinical trial NCT01802567?
This trial is sponsored by Giselle Sholler, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.